This phase I study will evaluate safety and tolerability after repeated doses of AZD0837.

Inclusion Criteria:

• Healthy male Japanese subject aged between 20 to 45 years inclusive

Exclusion Criteria:

• Acute illness (including ongoing or history of liver disease), trauma or surgical procedures within two weeks before Visit 1 or pre first dose in Visit 2
• Intake of another investigational drug within 4 months before Visit 1 or pre first dose in Visit 2
• Blood donation and/or sampling in excess of 200 mL of whole blood within the preceding 4 weeks, 400 mL of whole blood within the preceding 12 weeks and/or 1200 mL of whole blood within the preceding 12 months, before Visit 1 or pre first dose in Visit 2